Retatrutide, a triple agonist: early kidney signals

Evidence tier

Emerging / Investigational · Dual / triple agonist

Plain-language summary

Phase-2 post-hoc analyses showed reductions in urine albumin-to-creatinine ratio. Dedicated trials are ongoing: TRANSCEND-CKD (renal function by iohexol mGFR) with topline expected in 2026, and the pivotal phase-3 TRIUMPH-Outcomes programme not expected before 2028–2029. Investigational — no reported phase-3 kidney-outcome results yet.

Key findings

  • Phase-2 post-hoc: UACR reductions (~31–37% at 12 mg) and eGFR gains.
  • TRANSCEND-CKD (NCT05936151): phase-2b, mGFR, topline expected 2026.
  • TRIUMPH-Outcomes (NCT06383390): phase-3 CV + kidney outcomes, ~2028–2029.

Population

Adults with obesity and/or type 2 diabetes, with CKD in the dedicated renal study.

What this does not prove

No reported phase-3 kidney-outcome results yet; retatrutide is investigational and not approved. Post-hoc signals are hypothesis-generating.

Primary source

TRANSCEND-CKD NCT05936151; TRIUMPH-Outcomes NCT06383390.
https://clinicaltrials.gov/study/NCT06383390

Educational only

Paraphrased from the primary publication; not individual medical advice. Verify against the source before applying to care.